These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 19223641)

  • 1. Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection.
    Baines SD; Freeman J; Wilcox MH
    Antimicrob Agents Chemother; 2009 May; 53(5):2202-4. PubMed ID: 19223641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolevamer, an anionic polymer, neutralizes toxins produced by the BI/027 strains of Clostridium difficile.
    Hinkson PL; Dinardo C; DeCiero D; Klinger JD; Barker RH
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2190-5. PubMed ID: 18391047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea.
    Johnson S; Gerding DN; Louie TJ; Ruiz NM; Gorbach SL
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4043-5. PubMed ID: 22615287
    [No Abstract]   [Full Text] [Related]  

  • 4. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea.
    Louie TJ; Peppe J; Watt CK; Johnson D; Mohammed R; Dow G; Weiss K; Simon S; John JF; Garber G; Chasan-Taber S; Davidson DM;
    Clin Infect Dis; 2006 Aug; 43(4):411-20. PubMed ID: 16838228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis.
    Kurtz CB; Cannon EP; Brezzani A; Pitruzzello M; Dinardo C; Rinard E; Acheson DW; Fitzpatrick R; Kelly P; Shackett K; Papoulis AT; Goddard PJ; Barker RH; Palace GP; Klinger JD
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2340-7. PubMed ID: 11451694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physicochemical properties.
    Barker RH; Dagher R; Davidson DM; Marquis JK
    Aliment Pharmacol Ther; 2006 Dec; 24(11-12):1525-34. PubMed ID: 17206941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolevamer, an orally administered, toxin-binding polymer for Clostridium difficile-associated diarrhea.
    Scheinfeld N; Biggers K
    Curr Opin Investig Drugs; 2008 Aug; 9(8):913-24. PubMed ID: 18666039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model.
    Baines SD; Crowther GS; Freeman J; Todhunter S; Vickers R; Wilcox MH
    J Antimicrob Chemother; 2015 Jan; 70(1):182-9. PubMed ID: 25190720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microbial and metabolic interactions between the gastrointestinal tract and Clostridium difficile infection.
    Theriot CM; Young VB
    Gut Microbes; 2014; 5(1):86-95. PubMed ID: 24335555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer.
    Weiss K
    Int J Antimicrob Agents; 2009 Jan; 33(1):4-7. PubMed ID: 18804351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and evaluation of a PCR method for detection of the Clostridium difficile toxin B gene in stool specimens.
    Guilbault C; Labbé AC; Poirier L; Busque L; Béliveau C; Laverdière M
    J Clin Microbiol; 2002 Jun; 40(6):2288-90. PubMed ID: 12037113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model.
    Freeman J; Baines SD; Saxton K; Wilcox MH
    J Antimicrob Chemother; 2007 Jul; 60(1):83-91. PubMed ID: 17483547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.
    Johnson S; Louie TJ; Gerding DN; Cornely OA; Chasan-Taber S; Fitts D; Gelone SP; Broom C; Davidson DM;
    Clin Infect Dis; 2014 Aug; 59(3):345-54. PubMed ID: 24799326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clostridium difficile and cytotoxin in feces of patients with antimicrobial agent-associated pseudomembranous colitis.
    George WL; Rolfe RD; Harding GK; Klein R; Putnam CW; Finegold SM
    Infection; 1982; 10(4):205-8. PubMed ID: 7129642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences of the Fecal Microflora With Clostridium difficile Therapies.
    Louie TJ; Byrne B; Emery J; Ward L; Krulicki W; Nguyen D; Wu K; Cannon K
    Clin Infect Dis; 2015 May; 60 Suppl 2():S91-7. PubMed ID: 25922407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection.
    Chilton CH; Crowther GS; Baines SD; Todhunter SL; Freeman J; Locher HH; Athanasiou A; Wilcox MH
    J Antimicrob Chemother; 2014 Mar; 69(3):697-705. PubMed ID: 24128668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model.
    Baines SD; Noel AR; Huscroft GS; Todhunter SL; O'Connor R; Hobbs JK; Freeman J; Lovering AM; Wilcox MH
    J Antimicrob Chemother; 2011 Jul; 66(7):1537-46. PubMed ID: 21504940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clostridium difficile infection: new developments in epidemiology and pathogenesis.
    Rupnik M; Wilcox MH; Gerding DN
    Nat Rev Microbiol; 2009 Jul; 7(7):526-36. PubMed ID: 19528959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Auranofin, at clinically achievable dose, protects mice and prevents recurrence from Clostridioides difficile infection.
    Abutaleb NS; Seleem MN
    Sci Rep; 2020 May; 10(1):7701. PubMed ID: 32382070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clostridioides difficile biofilms: A mechanism of persistence in the gut?
    Frost LR; Cheng JKJ; Unnikrishnan M
    PLoS Pathog; 2021 Mar; 17(3):e1009348. PubMed ID: 33705497
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.